Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
Our newest portfolio stock backed off its recent 52-week high — so we're buying more
UnitedHealthcare CEO Brian Thompson fatally shot in New York
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
CDC says McDonald's E. coli outbreak is over
Medicare Graham: Your Trusted Guide to Navigating Medicare Plans
Healthy Returns: Trump’s FDA pick Makary may be a relief for biotech and pharma, analysts say
